Cabozantinib

In this video, Maria E. Cabanillas, MD, an oncologic endocrinologist at The University of Texas MD Anderson Cancer Center, discussed important research on immunotherapy combinations presented at American Thyroid Association Annual Meeting.

Cabozantinib combined with nivolumab and ipilimumab was "reasonably well tolerated," though it did not display an efficacy advantage over monotherapy, Bhavana Konda, MD, MPH, said in an interview with Healio.

This year’s European Society for Medical Oncology Congress featured potentially practice-changing research in kidney cancer, cutaneous squamous cell carcinoma, lung cancer and melanoma.

Cabozantinib plus nivolumab and ipilimumab conferred a significant PFS benefit vs. nivolumab and ipilimumab alone among patients with advanced renal cell carcinoma, according to results of the COSMIC-313 trial presented at ESMO Congress.

CHICAGO —Cabozantinib did not significantly extend progression-free survival in patients with metastatic urothelial carcinoma who had undergone platinum-based chemotherapy, according to data presented at ASCO Annual Meeting.

CHICAGO — Cabozantinib plus atezolizumab showed encouraging clinical activity in patients with inoperable locally advanced or metastatic urothelial carcinoma, according to data from the COSMIC-021 study.

CHICAGO — Deeper response to treatment was associated with improved progression-free and overall survival in patients with advanced renal cell carcinoma, according to data from the CheckMate 9ER trial.

The combination of cabozantinib and durvalumab appeared safe and demonstrated efficacy among a small cohort of patients with advanced mismatch repair-proficient/microsatellite-stable colorectal cancer, according to study results.

Cabozantinib demonstrated intracranial activity and appeared safe among patients with renal cell carcinoma and brain metastases, according to a study in JAMA Oncology.

Nivolumab plus cabozantinib improved outcomes compared with sunitinib regardless of prior nephrectomy among patients with advanced renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.